

## PHARMACY COVERAGE GUIDELINE

### General Coverage Guideline (For Medication Without Drug Specific Guideline)

---

#### **This Pharmacy Coverage Guideline (PCG):**

- Provides information about the reasons, basis, and information sources we use for coverage decisions
- Is not an opinion that a drug (collectively “Service”) is clinically appropriate or inappropriate for a patient
- Is not a substitute for a provider’s judgment (Provider and patient are responsible for all decisions about appropriateness of care)
- Is subject to all provisions e.g. (benefit coverage, limits, and exclusions) in the member’s benefit plan; and
- Is subject to change as new information becomes available.

#### **Scope**

- This PCG applies to Commercial and/or Marketplace plans
- This PCG does not apply to the Federal Employee Program, Medicare Advantage, Medicaid or members of out-of-state Blue Cross and/or Blue Shield Plans

#### **Instructions & Guidance**

- To determine whether a member is eligible for the Service, read the entire PCG.
- This PCG is used for FDA approved indications including, but not limited to, a diagnosis and/or treatment with dosing, frequency, and duration.
- Use of a drug outside the FDA approved guidelines, refer to the appropriate Off-Label Use policy.
- The “Criteria” section outlines the factors and information we use to decide if the Service is medically necessary as defined in the Member’s benefit plan.
- The “Description” section describes the Service.
- The “Definition” section defines certain words, terms or items within the policy and may include tables and charts.
- The “Resources” section lists the information and materials we considered in developing this PCG
- **We do not accept patient use of samples as evidence of an initial course of treatment, justification for continuation of therapy, or evidence of adequate trial and failure.**
- Information about medications that require prior authorization is available at [www.azblue.com/pharmacy](http://www.azblue.com/pharmacy). You must fully complete the [request form](#) and provide chart notes, lab workup and any other supporting documentation. The prescribing provider must sign the form. Fax the form to BCBSAZ Pharmacy Management at (602) 864-3126 or email it to [Pharmacyprecert@azblue.com](mailto:Pharmacyprecert@azblue.com).

---

## Medical Necessity Requirements for **MEDICATIONS WITHOUT DRUG SPECIFIC GUIDELINES**

### Criteria for Initial Therapy:

#### **Prescriber Qualifications**

- Prescribed by a physician specializing in the diagnosis or is in consultation with a physician in the clinically appropriate specialty

#### **Indication**

- Diagnosis, dosage, duration, and indication for use must be consistent with the United States Food and Drug Administration (FDA)-approved product labeling

## PHARMACY COVERAGE GUIDELINE

### General Coverage Guideline (For Medication Without Drug Specific Guideline)

---

#### Age Requirement

- Age consistent with the FDA-approved product labeling

#### Baseline Clinical Evaluation

- Completed all required baseline tests cited in the FDA-approved product labeling before starting treatment
- Continued monitoring as clinically appropriate
- Individual does not have a conflicting benefit exclusion

#### Alternative Therapies

- Meets **ONE** of the following:
  - Failure, contraindication, intolerance, or is not a candidate for **TWO** alternative medications with similar mechanism of action
  - If no similar mechanism medications available: failure, contraindication, intolerance, or is not a candidate for **TWO** alternative medications that are medically acceptable to treat the condition
  - Failure, contraindication, intolerance, or is not a candidate for an FDA-approved generic or biosimilar equivalent (if available)
  - No alternative medications are medically acceptable to treat the condition

#### Brand Specific Criteria

- Have failure, contraindication, or intolerance with **THREE** generic equivalents (if available) for at least three months each. **Note:** Any failure, contraindication, or intolerance to the generic drugs should be reported to the United States Food and Drug Administration (FDA) (see Definitions section)

#### Safety

- No FDA-label contraindications or other significant exclusions
- Agent's use has established safety and efficacy for the condition or diagnosis
- No significant interacting drugs

#### Documentation Requirements

- A completed request form must be submitted including:
  - Chart notes
  - Lab results
  - Supporting clinical documentation

#### Initial Therapy Criteria Approval Duration

- 6 months (or as subject to limitations found in the FDA-approved product labeling) OR end of plan year

---

### Criteria for Continuation of Therapy (renewal therapy):

**Note: Manufacturer assistance (e.g., coupons, samples, etc.) are not considered for continuation of therapy.**

#### Prescriber Qualification

- Continues to be seen by a physician specializing in the diagnosis or is in consultation with a physician in the clinically appropriate specialty

#### Clinical Response

ORIGINAL EFFECTIVE DATE: 07/16/2015 | ARCHIVE DATE: | LAST REVIEW DATE: 02/19/2026 | LAST CRITERIA REVISION DATE: 02/15/2024

BLUE CROSS®, BLUE SHIELD® and the Cross and Shield Symbols are registered service marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield Plans. All other trademarks and service marks contained in this guideline are the property of their respective owners, which are not affiliated with BCBSAZ.

## PHARMACY COVERAGE GUIDELINE

### General Coverage Guideline (For Medication Without Drug Specific Guideline)

---

- **ALL** of the following:
  - No evidence of disease progression
  - Documented evidence of efficacy and/or improvement
  - Maintains most activities of daily living

#### Adherence

- Adherence to the prescribed therapy regimen has been documented

#### Brand Specific Criteria

- Have failure, contraindication, or intolerance with **THREE** generic equivalents (if available) for at least three months each. **Note:** Any failure, contraindication, or intolerance to the generic drugs should be reported to the United States Food and Drug Administration (FDA) (see Definitions section)

#### Safety

- No new contraindications or significant adverse drug effects
- No significant interacting drugs

#### Documentation Requirements

- Chart notes
- Supporting clinical documentation with evidence of improvement in given indication
- Lab values that confirm safe use

#### Continuation Therapy Criteria Approval Duration

- 12 months (or as subject to limitations found in the FDA-approved product labeling) OR end of plan year
- 

### Criteria for Off-Label Use Requests:

Criteria for a request for non-FDA use or indication, treatment with dosing, frequency, or duration outside the FDA-approved dosing, frequency, and duration, refer to one of the following Pharmacy Coverage Guideline:

1. Off-Label Use of Non-Cancer Medications
  2. Off-Label Use of Cancer Medications
- 

#### Description:

BCBSAZ benefits require that medications are FDA approved. General medication requests for agents that require prior authorization but do not have a specific pharmacy coverage guideline must include the medication name, dose, frequency, route of administration, length of therapy anticipated, other agents tried previously with information on failure or ineffective treatments or adverse drug events or contraindications or non-adherence, disease or condition being treated including the severity, and all applicable laboratory and other test results. Additional information submitted by the prescriber will also be reviewed (e.g., clinical articles from the literature, clinical guidelines, etc.).

## PHARMACY COVERAGE GUIDELINE

### General Coverage Guideline (For Medication Without Drug Specific Guideline)

---

#### Definitions:

U.S. Food and Drug Administration (FDA) MedWatch Forms for FDA Safety Reporting  
[MedWatch Forms for FDA Safety Reporting | FDA](#)

**FDA:** Food and Drug Administration

**Medication Product Labeling:** Manufacturer FDA approved product information

**Medically acceptable:** Medications that may be considered as medically acceptable alternative medications should meet the standards for safety and efficacy for the indication requested as defined below:

- Medication is FDA approved for the same indication
- Medication is recognized to be safe and effective for indication requested and is supported by **ONE** of the nationally recognized compendia, guidelines or literature:
  - American Hospital Formulary Service Clinical Drug Information with narrative text of “supportive”
  - IBM Micromedex compendium that meets **ALL** of the following:
    - Strength of Recommendation of Class I or IIa
    - Strength of Evidence Category A or B
    - Strength of Efficacy Class I or IIa (evidence favors efficacy)
  - Elsevier Gold Standard’s Clinical Pharmacology compendium with narrative text of “supportive”
  - Wolters Kluwer Lexi-Drugs with use listed as “off-label, evidence level A”
  - Other authoritative reference as identified by the Secretary of the United States Department of Human Health Services
  - National Comprehensive Cancer Network (NCCN) Guidelines with Categories of Evidence and Consensus of 1 and 2A
  - At least **TWO** articles from major peer reviewed professional medical journals that have recognized, based on scientific or medical criteria, the safety and effectiveness for the exception on medical limitation for age, gender, quantity, or dosage

---

#### Resources:

FDA-approved product labeling guideline revised by Manufacturer. Available at DailyMed <http://dailymed.nlm.nih.gov>.

Off Label Use of Cancer Medications: A.R.S. §§ 20-826® & (S). Subscription contracts; definitions.

Off Label Use of Cancer Medications: A.R.S. §§ 20-1057(V) & (W). Evidence of coverage by health care service organizations; renewability; definitions